二、持有人会议审议情况 证券代码：300451 证券简称：创业慧康 公告编号：2025-066 创业慧康科技股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、持有人会议召开情况 创业慧康科技股份有限公司（以下简称"公司"或"创业慧康"）2025 年员工持 股计划（以下简称"本持股计划"）第一次持有人会议于 2025 年 11 月 3 日在公司 会议室以现场结合通讯的方式召开，出席本次会议的持有人共计 28 人，代表本 持股计划份额 12,262,302 份，占本持股计划总份额的 100%。本次会议由公司董 事会秘书胡燕女士召集和主持，本次会议的召开符合《创业慧康科技股份有限公 司 2025 年员工持股计划（草案）》《创业慧康科技股份有限公司 2025 年员工持 股计划管理办法》及相关法律、法规、规范性文件的规定，会议决议合法、有效。 （一）审议通过了《关于设立 2025 年员工持股计划管理委员会的议案》 为保证 2025 年员工持股计划的顺利进行，保障持有人的合法权益，根据《创 业慧康科技股份有限公 ...

Core Viewpoint - Chuangye Huikang Technology Co., Ltd. is a leading enterprise in the domestic healthcare information technology sector, focusing on software and system integration for healthcare informationization, with a full industry chain service capability [1] Group 1: Business Performance - In Q3 2025, Chuangye Huikang achieved a revenue of 862 million yuan, ranking 29th among 102 companies in the industry, while the industry leader, Shanghai Steel Union, reported a revenue of 57.318 billion yuan [2] - The company's net profit for the same period was -107 million yuan, placing it 89th in the industry, with the top performer, Desay SV, reporting a net profit of 1.805 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Chuangye Huikang's debt-to-asset ratio was 20.27%, an increase from 19.01% year-on-year, which is lower than the industry average of 31.94%, indicating strong debt repayment capability [3] - The gross profit margin for the same period was 49.87%, slightly down from 50.14% year-on-year, but still above the industry average of 41.71%, reflecting good profitability [3] Group 3: Executive Compensation - The chairman, Zhang Lvzhen, received a salary of 1.0848 million yuan in 2024, a slight decrease from 1.0858 million yuan in 2023 [4] - The general manager, Chen Zhongyang, earned 1.4098 million yuan in 2024, significantly up from 420,400 yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.69% to 64,400, while the average number of circulating A-shares held per shareholder increased by 0.70% to 23,700 [5] - Major shareholders included Noan Active Return Mixed A, which held 16.108 million shares, down by 8.0292 million shares from the previous period [5] Group 5: Market Outlook - Huatai Securities noted that the decline in revenue and profit in the first three quarters of 2025 was due to short-term market pressures and the lack of scale revenue from new products, but performance is expected to recover with industry demand [5] - Zhongtai Securities adjusted its revenue forecasts for 2025-2027 to 1.468 billion, 1.592 billion, and 1.794 billion yuan, respectively, with net profits projected at 50 million, 130 million, and 216 million yuan [6]

证券之星消息，截至2025年10月31日收盘，创业慧康(300451)报收于4.76元，上涨3.48%，换手率 3.32%，成交量50.73万手，成交额2.39亿元。 10月31日的资金流向数据方面，主力资金净流出1671.89万元，占总成交额6.99%，游资资金净流入 143.97万元，占总成交额0.6%，散户资金净流入1527.92万元，占总成交额6.39%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-31 | 4.76 3.48% | -1671.89万 | -6.99% | 143.97万 | 0.60% | 1527.92万 | - 6.39% | | 2025-10-30 | 4.60 -0.86% | -1218.18万 | -9.73% | 310.55万 | 2.48% | 907.63万 | 7.25% | | 2025-10-29 | 4.64 -1.07% | -2 ...

关于 2025 年员工持股计划完成非交易过户的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本员工持股计划的股份来源为公司回购专用账户回购的公司 A 股普通股股 票。公司于 2023 年 8 月 22 日召开第七届董事会第三十次会议和第七届监事会第 二十四次会议审议通过《关于回购公司股份方案的议案》，同意公司使用自有资 金以集中竞价交易的方式回购公司部分人民币普通 A 股股票，全部用于实施员 工持股及、或股权激励计划，独立董事发表了明确同意的独立意见。2023 年 9 月 11 日，公司通过股份回购专用证券账户以集中竞价方式实施了首次回购。截 至 2023 年 9 月 30 日，公司回购方案已实施完成，公司通过股份回购专用证券账 户以集中竞价交易的方式累计回购股份 4,698,200 股，约占公司总股本的比例为 0.30%，最高成交价为 6.82 元/股，最低成交价为 6.41 元/股，成交总金额为 30,985,281.00 元（不含交易费用）。具体内容详见公司在巨潮资讯网披露的相关 公告。 本员工持股计划通过非交易过户方式受让公司回购股份数量为 4,6 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 6.05 RMB [7][5]. Core Views - The company's revenue and profit have declined significantly due to market pressures, delayed customer demand, and project acceptance delays, leading to a revenue drop of 26.26% year-on-year in the first three quarters of 2025 [1]. - Despite the current challenges, the report suggests that the company's performance is expected to recover as industry demand improves, supported by the introduction of new products and successful project deliveries [1][3]. - The company has made significant strides in the AI and data service market, launching an AI medical intelligence system that enhances its traditional software offerings and shifts its business model towards "software + data services" [3][4]. Revenue and Profitability - For the first three quarters of 2025, the company reported revenues of 862 million RMB, a decrease of 26.26% year-on-year, and a net profit attributable to shareholders of -122 million RMB, compared to a profit of 53 million RMB in the same period last year [1]. - The gross margin for the first three quarters was 49.87%, showing a slight decrease of 0.27 percentage points year-on-year, while the gross margin for Q3 2025 was 46.69%, an increase of 3.24 percentage points year-on-year [2]. Cost Structure - The report highlights an increase in sales, management, and R&D expense ratios due to the decline in revenue, with sales expenses at 8.35%, management expenses at 19.65%, and R&D expenses at 25.89% for Q3 2025 [2]. - The company has achieved a 20% increase in the number of million-level orders and a 7% increase in order value in the major customer market, indicating a positive trend despite overall revenue decline [2]. Market Position and Future Outlook - The company has established itself as a key player in the medical information technology sector, achieving comprehensive compatibility with domestic technology routes and enhancing data security and autonomy for hospitals [4]. - The report projects a revenue forecast adjustment for 2025, 2026, and 2027, with expected revenues of 1.21 billion RMB, 1.34 billion RMB, and 1.48 billion RMB respectively, reflecting a downward adjustment of 25%, 27%, and 28% due to delayed project bidding [5][13].

Group 1 - The core viewpoint of the news is that Chuangye Huikang (300451.SZ) reported a decrease in institutional holdings in its third-quarter report for 2025, with a total of 7 institutional investors holding 278 million shares, accounting for 17.96% of the total share capital, which is a decline of 0.76 percentage points compared to the previous quarter [1] - Among public funds, there were 2 funds that reduced their holdings compared to the previous quarter, with a total reduction of 0.52% [1] - A total of 88 public funds did not disclose their holdings this quarter, including several notable funds such as Guorong Rongsheng Longtou Yanxuan Mixed A and Huaxia Zhongzheng 1000 ETF [1] Group 2 - For social security funds, there was 1 fund that did not disclose its holdings this quarter, specifically the E Fund Management Co., Ltd. - Social Security Fund 17042 portfolio [2] - In terms of foreign investment, there was 1 foreign institution that did not disclose its holdings this quarter, namely Hong Kong Central Clearing Limited [2]

Core Viewpoint - The company reported a significant decline in revenue and incurred net losses in the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 862 million yuan, representing a year-on-year decrease of 26.26% [1] - The net loss attributable to shareholders of the listed company was 122 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 142 million yuan [1] - The basic loss per share was 0.08 yuan [1]

Core Points - The company announced a financial adjustment to reflect its financial status and operating results accurately for the period from July 1, 2025, to September 30, 2025 [2] - The company conducted impairment testing on various assets as of September 30, 2025, and, based on the principle of prudence, recognized a total impairment provision of RMB 29,826,588.56 [2] Financial Impact - The total amount of impairment provisions recognized by the company is approximately RMB 29.83 million [2]

Group 1 - The core viewpoint of the news is that Chuangye Huikang (SZ 300451) reported a significant decline in its third-quarter performance for 2025, with revenue dropping by 26.26% year-on-year to approximately 862 million yuan, and a net loss attributable to shareholders of about 122 million yuan [1] - The basic earnings per share for the company showed a loss of 0.08 yuan [1] - As of the report, Chuangye Huikang's market capitalization stands at 7.3 billion yuan [2]

Group 1 - The company, Chuangye Huikang, announced a provision for credit impairment and asset impairment totaling approximately 29.83 million yuan for the third quarter of 2025, which aligns with the "Enterprise Accounting Standards" and relevant policies [1] - This provision will reduce the company's total profit for the third quarter of 2025 by about 29.83 million yuan, reflecting a more accurate and reliable accounting of the company's asset value [1] - For the first half of 2025, the company's revenue composition was 94.1% from the medical industry and 5.9% from other businesses [1] Group 2 - As of the report, the market capitalization of Chuangye Huikang is 7.3 billion yuan [2]